MS Pharma Signs an Agreement for Hepatitis A Vaccine – HEALIVE®
MS PHARMA VENTURES HOLDING W.L.L announces a license, supply and distribution agreement with SINOVAC BIOTECH CO., LTD. for Sinovac’s WHO PQ approved Hepatitis A vaccine HEALIVE® for the Jordanian market.
Hepatitis A vaccine demand has recently been reintroduced in the National Vaccination Program in Jordan. HEALIVE® vaccine, manufactured by Sinovac, has passed the assessment under WHO Prequalification procedures in 2017.
This step comes at the heart of MS Pharma’s crucial strategy to supply the pharmaceutical market with outstanding products covering unmet needs in specialized and advanced therapeutic areas.
Dr. Essam Farouk – MS Pharma’ CEO stated in this occasion “our commitment is to serve our communities and improve the standard of health in our local market and other countries of presence, by partnering with global innovative external pharmaceutical companies”.
Sinovac management team as well assured the importance on such step that helps in reaching more patients with new medications that will help improve the community’s health in the Middle East and Africa by collaborating with well-established regional pharmaceutical company.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.
About MS Pharma
MS Pharma is a leading pharmaceutical company and strategic partner in the Middle East, Africa, Turkey, and Europe. The company is based in Jordan, has several plants in Jordan, Algeria, Greece, Saudi Arabia, and Turkey, and exports to over 60 countries worldwide. The company has the capability to manufacture branded generics and oncology products in different dosage forms including oral, topical and injectable forms.